Storys zum Thema Adalimumab

STADA Arzneimittel AG

Press release: STADA continues strong growth journey in the first half of 2024

STADA Arzneimittel AG

Press release: Alvotech and STADA add to strategic alliance through denosumab partnership

Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...

STADA Arzneimittel AG

Press release: STADA continues with double-digit sales and profit growth in 2023

STADA Arzneimittel AG

Press release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...

STADA Arzneimittel AG

Press release: STADA and Xbrane launch ranibizumab to support patient access in Europe

STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...

STADA Arzneimittel AG

Press release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...

STADA Arzneimittel AG

Press release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe

Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...